Literature DB >> 21196496

The structure of NSD1 reveals an autoregulatory mechanism underlying histone H3K36 methylation.

Qi Qiao1, Yan Li, Zhi Chen, Mingzhu Wang, Danny Reinberg, Rui-Ming Xu.   

Abstract

The Sotos syndrome gene product, NSD1, is a SET domain histone methyltransferase that primarily dimethylates nucleosomal histone H3 lysine 36 (H3K36). To date, the intrinsic properties of NSD1 that determine its nucleosomal substrate selectivity and dimethyl H3K36 product specificity remain unknown. The 1.7 Å structure of the catalytic domain of NSD1 presented here shows that a regulatory loop adopts a conformation that prevents free access of H3K36 to the bound S-adenosyl-L-methionine. Molecular dynamics simulation and computational docking revealed that this normally inhibitory loop can adopt an active conformation, allowing H3K36 access to the active site, and that the nucleosome may stabilize the active conformation of the regulatory loop. Hence, our study reveals an autoregulatory mechanism of NSD1 and provides insight into the molecular mechanism of the nucleosomal substrate selectivity of this disease-related H3K36 methyltransferase.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21196496      PMCID: PMC3048720          DOI: 10.1074/jbc.M110.204115

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  48 in total

1.  NUP98 is fused to the NSD3 gene in acute myeloid leukemia associated with t(8;11)(p11.2;p15).

Authors:  Roberto Rosati; Roberta La Starza; Angelo Veronese; Ana Aventin; Christine Schwienbacher; Teresa Vallespi; Massimo Negrini; Massimo F Martelli; Cristina Mecucci
Journal:  Blood       Date:  2002-05-15       Impact factor: 22.113

2.  Set2 is a nucleosomal histone H3-selective methyltransferase that mediates transcriptional repression.

Authors:  Brian D Strahl; Patrick A Grant; Scott D Briggs; Zu-Wen Sun; James R Bone; Jennifer A Caldwell; Sahana Mollah; Richard G Cook; Jeffrey Shabanowitz; Donald F Hunt; C David Allis
Journal:  Mol Cell Biol       Date:  2002-03       Impact factor: 4.272

3.  Structure of the Neurospora SET domain protein DIM-5, a histone H3 lysine methyltransferase.

Authors:  Xing Zhang; Hisashi Tamaru; Seema I Khan; John R Horton; Lisa J Keefe; Eric U Selker; Xiaodong Cheng
Journal:  Cell       Date:  2002-10-04       Impact factor: 41.582

4.  NSD1 mutations are the major cause of Sotos syndrome and occur in some cases of Weaver syndrome but are rare in other overgrowth phenotypes.

Authors:  Jenny Douglas; Sandra Hanks; I Karen Temple; Sally Davies; Alexandra Murray; Meena Upadhyaya; Susan Tomkins; Helen E Hughes; Trevor R P Cole; Nazneen Rahman
Journal:  Am J Hum Genet       Date:  2002-12-02       Impact factor: 11.025

5.  Structure of the catalytic domain of human DOT1L, a non-SET domain nucleosomal histone methyltransferase.

Authors:  Jinrong Min; Qin Feng; Zhizhong Li; Yi Zhang; Rui-Ming Xu
Journal:  Cell       Date:  2003-03-07       Impact factor: 41.582

6.  NSD3, a new SET domain-containing gene, maps to 8p12 and is amplified in human breast cancer cell lines.

Authors:  P O Angrand; F Apiou; A F Stewart; B Dutrillaux; R Losson; P Chambon
Journal:  Genomics       Date:  2001-05-15       Impact factor: 5.736

7.  Association of the histone methyltransferase Set2 with RNA polymerase II plays a role in transcription elongation.

Authors:  Jiaxu Li; Danesh Moazed; Steven P Gygi
Journal:  J Biol Chem       Date:  2002-10-14       Impact factor: 5.157

8.  A novel gene, NSD1, is fused to NUP98 in the t(5;11)(q35;p15.5) in de novo childhood acute myeloid leukemia.

Authors:  R J Jaju; C Fidler; O A Haas; A J Strickson; F Watkins; K Clark; N C Cross; J F Cheng; P D Aplan; L Kearney; J Boultwood; J S Wainscoat
Journal:  Blood       Date:  2001-08-15       Impact factor: 22.113

9.  Haploinsufficiency of NSD1 causes Sotos syndrome.

Authors:  Naohiro Kurotaki; Kiyoshi Imaizumi; Naoki Harada; Mitsuo Masuno; Tatsuro Kondoh; Toshiro Nagai; Hirofumi Ohashi; Kenji Naritomi; Masato Tsukahara; Yoshio Makita; Tateo Sugimoto; Tohru Sonoda; Tomoko Hasegawa; Yasuaki Chinen; Hiro-aki Tomita Ha; Akira Kinoshita; Tsuyoshi Mizuguchi; Koh-ichiro Yoshiura Ki; Tohru Ohta; Tatsuya Kishino; Yoshimitsu Fukushima; Norio Niikawa; Naomichi Matsumoto
Journal:  Nat Genet       Date:  2002-03-18       Impact factor: 38.330

10.  Structure and catalytic mechanism of the human histone methyltransferase SET7/9.

Authors:  Bing Xiao; Chun Jing; Jonathan R Wilson; Philip A Walker; Nishi Vasisht; Geoff Kelly; Steven Howell; Ian A Taylor; G Michael Blackburn; Steven J Gamblin
Journal:  Nature       Date:  2003-01-22       Impact factor: 49.962

View more
  76 in total

Review 1.  Understanding the language of Lys36 methylation at histone H3.

Authors:  Eric J Wagner; Phillip B Carpenter
Journal:  Nat Rev Mol Cell Biol       Date:  2012-01-23       Impact factor: 94.444

2.  Transition state for the NSD2-catalyzed methylation of histone H3 lysine 36.

Authors:  Myles B Poulin; Jessica L Schneck; Rosalie E Matico; Patrick J McDevitt; Michael J Huddleston; Wangfang Hou; Neil W Johnson; Sara H Thrall; Thomas D Meek; Vern L Schramm
Journal:  Proc Natl Acad Sci U S A       Date:  2016-01-19       Impact factor: 11.205

Review 3.  SET for life: biochemical activities and biological functions of SET domain-containing proteins.

Authors:  Hans-Martin Herz; Alexander Garruss; Ali Shilatifard
Journal:  Trends Biochem Sci       Date:  2013-10-20       Impact factor: 13.807

4.  Histone H2A ubiquitination inhibits the enzymatic activity of H3 lysine 36 methyltransferases.

Authors:  Gang Yuan; Ben Ma; Wen Yuan; Zhuqiang Zhang; Ping Chen; Xiaojun Ding; Li Feng; Xiaohua Shen; She Chen; Guohong Li; Bing Zhu
Journal:  J Biol Chem       Date:  2013-09-09       Impact factor: 5.157

Review 5.  The Role of Nuclear Receptor-Binding SET Domain Family Histone Lysine Methyltransferases in Cancer.

Authors:  Richard L Bennett; Alok Swaroop; Catalina Troche; Jonathan D Licht
Journal:  Cold Spring Harb Perspect Med       Date:  2017-06-01       Impact factor: 6.915

6.  An open and shut case for the role of NSD proteins as oncogenes.

Authors:  Agda Karina Lucio-Eterovic; Phillip B Carpenter
Journal:  Transcription       Date:  2011-07

Review 7.  Inhibitors of Protein Methyltransferases and Demethylases.

Authors:  H Ümit Kaniskan; Michael L Martini; Jian Jin
Journal:  Chem Rev       Date:  2017-03-24       Impact factor: 60.622

8.  Impaired H3K36 methylation defines a subset of head and neck squamous cell carcinomas.

Authors:  Simon Papillon-Cavanagh; Chao Lu; Tenzin Gayden; Leonie G Mikael; Denise Bechet; Christina Karamboulas; Laurie Ailles; Jason Karamchandani; Dylan M Marchione; Benjamin A Garcia; Ilan Weinreb; David Goldstein; Peter W Lewis; Octavia Maria Dancu; Sandeep Dhaliwal; William Stecho; Christopher J Howlett; Joe S Mymryk; John W Barrett; Anthony C Nichols; C David Allis; Jacek Majewski; Nada Jabado
Journal:  Nat Genet       Date:  2017-01-09       Impact factor: 38.330

9.  Two Loops Undergoing Concerted Dynamics Regulate the Activity of the ASH1L Histone Methyltransferase.

Authors:  David S Rogawski; Juliano Ndoj; Hyo Je Cho; Ivan Maillard; Jolanta Grembecka; Tomasz Cierpicki
Journal:  Biochemistry       Date:  2015-08-25       Impact factor: 3.162

Review 10.  H3K36 methyltransferases as cancer drug targets: rationale and perspectives for inhibitor development.

Authors:  David S Rogawski; Jolanta Grembecka; Tomasz Cierpicki
Journal:  Future Med Chem       Date:  2016-08-22       Impact factor: 3.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.